Tidepool Loop News Today

In this endocrinology month in review for March 2024, we recap the most popular FDA news and pipeline updates as well as recognizing the 2-year anniversary of Diabetes Dialogue.

Type 1 diabetes, often referred to as "juvenile diabetes" or "insulin-dependent diabetes," is a chronic autoimmune condition characterized by the panc

A community of people with type 1 diabetes got a self-built device approved. What can they offer that big companies can’t? A community of people with type 1 diabetes got a self-built device approved. What can they offer that big companies can’t?

The Insulin Pumps Market revenues were estimated at US$ 5.5 Bn in 2022 and are anticipated to grow at a CAGR of 10.3% from 2022-2032, according to a recently published Future Market Insights report. By the end of 2032, the market is expected to reach US$ 14.8 Bn. The demand for tethered pumps is projected to garner...

Innovations in drug delivery never stop, and over the past 12 months or so, a wide variety of them have come under the spotlight.

PARSIPPANY, N.J., May 12, 2023 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta" or the "Company") (Nasdaq: EMBC), one of the largest pure-play diabetes care companies in the world, today reported financial

The top 10 most popular FDA approval articles from the first quarter of 2023, with an additional spotlight on other top regulatory news from the first 3 months of the year.

The FDA has cleared Tidepool Loop, an automated insulin dosing mobile application to help manage type 1 diabetes.

The Tidepool Loop app connects to compatible continuous glucose monitors and pumps and helps Type 1 diabetes patients determine whether insulin levels should be adjusted.

Prescription-only device works with compatible continuous glucose monitors and insulin pumps for people with type 1 diabetes aged 6 years or older.